Scott Schliebner

Mr. Schliebner is a clinical strategist with a 25+ year background in clinical drug development focused on rare diseases, orphan drugs, and advanced therapeutics.  He develops innovative solutions and strategic considerations to help overcome the operational, logistical, and ethical challenges inherent to conducting research in challenging patient populations.  Mr. Schliebner’s efforts are focused on patient-centered approaches to drug development; reducing the burden of clinical trial participation; and leveraging virtual and de-centralized paradigms to bring new therapies to patients faster.  Mr. Schliebner also serves as the Co-Chair of Global Genes’ Corporate Alliance, and serves on the Board of Uplifting Athletes.  He holds a Master’s Degree in Public Health (MPH) from the University of Utah School of Medicine, and completed a Graduate Research Fellowship at The National Institutes of Health.